MX2018010894A - Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. - Google Patents
Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.Info
- Publication number
- MX2018010894A MX2018010894A MX2018010894A MX2018010894A MX2018010894A MX 2018010894 A MX2018010894 A MX 2018010894A MX 2018010894 A MX2018010894 A MX 2018010894A MX 2018010894 A MX2018010894 A MX 2018010894A MX 2018010894 A MX2018010894 A MX 2018010894A
- Authority
- MX
- Mexico
- Prior art keywords
- phosfatidilinositol
- quinasa
- new
- gamma inhibitors
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102000038030 PI3Ks Human genes 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen determinados nuevos compuestos (incluyendo sales farmacéuticamente aceptables de los mismos), (ver Fórmula) que inhiben la actividad de fosfatidilinositol 3-quinasa gamma (PI3K?), a su utilidad en tratar y/o prevenir afecciones clínicas, incluyendo enfermedades respiratorias tales como asma y enfermedad pulmonar obstructiva crónica (COPD), a su uso en terapia, a composiciones farmacéuticas que los contienen y a procedimientos para preparar estos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306328P | 2016-03-10 | 2016-03-10 | |
| PCT/EP2017/055552 WO2017153527A1 (en) | 2016-03-10 | 2017-03-09 | Novel inhibitors of phosphatidylinositol 3-kinase gamma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018010894A true MX2018010894A (es) | 2018-11-09 |
| MX387125B MX387125B (es) | 2025-03-18 |
Family
ID=58264542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010894A MX387125B (es) | 2016-03-10 | 2017-03-09 | Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10858355B2 (es) |
| EP (1) | EP3426652B1 (es) |
| JP (1) | JP6893520B2 (es) |
| KR (1) | KR20180117693A (es) |
| CN (1) | CN108779110B (es) |
| AR (1) | AR107840A1 (es) |
| AU (1) | AU2017229445B2 (es) |
| BR (1) | BR112018068075A2 (es) |
| CA (1) | CA3015893C (es) |
| EA (1) | EA036388B1 (es) |
| MX (1) | MX387125B (es) |
| TW (1) | TWI746525B (es) |
| WO (1) | WO2017153527A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
| WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
| WO2020102150A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
| ES3053348T3 (en) * | 2019-04-10 | 2026-01-21 | Nanjing Zenshine Pharmaceuticals Co Ltd | Phosphatidylinositol 3-kinase inhibitors |
| EP3980010A4 (en) | 2019-06-04 | 2023-06-07 | Arcus Biosciences, Inc. | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS |
| WO2022017371A1 (zh) * | 2020-07-21 | 2022-01-27 | 中国医药研究开发中心有限公司 | 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途 |
| CN115611883B (zh) * | 2021-07-13 | 2025-03-28 | 生物岛实验室 | 一种双环结构的PI3Kα抑制剂及其制备方法和用途 |
| CN119768404A (zh) * | 2022-09-01 | 2025-04-04 | 上海海雁医药科技有限公司 | 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用 |
| EP4585596A4 (en) * | 2022-09-09 | 2025-12-10 | Shanghai Yingli Pharm Co Ltd | Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| WO2025003330A1 (en) | 2023-06-30 | 2025-01-02 | Forschungsverbund Berlin E.V. | Thiazolo tetrahydrochinoline compounds as class ii phosphoinositide 3-kinase inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| EP1885356A2 (en) * | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| EA200801716A1 (ru) * | 2006-01-18 | 2009-04-28 | Амген Инк. | Тиазольные соединения и их применение |
| CN101484452A (zh) * | 2006-05-03 | 2009-07-15 | 阿斯利康(瑞典)有限公司 | 噻唑衍生物及其作为抗肿瘤药物的用途 |
| EP1894931A1 (en) * | 2006-08-30 | 2008-03-05 | Cellzome Ag | Triazole derivatives as kinase inhibitors |
| EP2327704A4 (en) * | 2008-08-29 | 2012-05-09 | Shionogi & Co | RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT |
| AU2010216219A1 (en) * | 2009-02-17 | 2011-09-01 | Vertex Pharmaceuticals Incorporated | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase |
| US20120040950A1 (en) * | 2009-12-22 | 2012-02-16 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
| CN104379573A (zh) * | 2012-04-20 | 2015-02-25 | 艾伯维公司 | 异吲哚酮衍生物 |
| US10301304B2 (en) | 2013-09-25 | 2019-05-28 | Vertex Pharmaceuticals Incorporated | Selective inhibitor of phosphatidylinositol 3-kinase-gamma |
| PL3134395T3 (pl) | 2014-04-24 | 2018-07-31 | Novartis Ag | Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu |
| BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
| JP6433509B2 (ja) | 2014-04-24 | 2018-12-05 | ノバルティス アーゲー | ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体 |
-
2017
- 2017-03-09 EA EA201891931A patent/EA036388B1/ru not_active IP Right Cessation
- 2017-03-09 TW TW106107711A patent/TWI746525B/zh not_active IP Right Cessation
- 2017-03-09 BR BR112018068075A patent/BR112018068075A2/pt not_active IP Right Cessation
- 2017-03-09 EP EP17709681.5A patent/EP3426652B1/en active Active
- 2017-03-09 AU AU2017229445A patent/AU2017229445B2/en not_active Ceased
- 2017-03-09 AR ARP170100589A patent/AR107840A1/es unknown
- 2017-03-09 MX MX2018010894A patent/MX387125B/es unknown
- 2017-03-09 KR KR1020187028625A patent/KR20180117693A/ko not_active Abandoned
- 2017-03-09 JP JP2018547461A patent/JP6893520B2/ja not_active Expired - Fee Related
- 2017-03-09 WO PCT/EP2017/055552 patent/WO2017153527A1/en not_active Ceased
- 2017-03-09 US US16/082,880 patent/US10858355B2/en not_active Expired - Fee Related
- 2017-03-09 CN CN201780014898.XA patent/CN108779110B/zh not_active Expired - Fee Related
- 2017-03-09 CA CA3015893A patent/CA3015893C/en active Active
-
2020
- 2020-11-04 US US17/088,689 patent/US20210047312A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018068075A2 (pt) | 2019-01-08 |
| US10858355B2 (en) | 2020-12-08 |
| KR20180117693A (ko) | 2018-10-29 |
| TW201808945A (zh) | 2018-03-16 |
| JP6893520B2 (ja) | 2021-06-23 |
| CN108779110A (zh) | 2018-11-09 |
| TWI746525B (zh) | 2021-11-21 |
| EP3426652B1 (en) | 2021-12-01 |
| CA3015893C (en) | 2021-11-09 |
| AR107840A1 (es) | 2018-06-13 |
| EA036388B1 (ru) | 2020-11-03 |
| EA201891931A1 (ru) | 2019-04-30 |
| WO2017153527A1 (en) | 2017-09-14 |
| AU2017229445B2 (en) | 2019-07-11 |
| AU2017229445A1 (en) | 2018-10-25 |
| MX387125B (es) | 2025-03-18 |
| US20210047312A1 (en) | 2021-02-18 |
| EP3426652A1 (en) | 2019-01-16 |
| JP2019507788A (ja) | 2019-03-22 |
| US20200299289A1 (en) | 2020-09-24 |
| CA3015893A1 (en) | 2017-09-14 |
| CN108779110B (zh) | 2021-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010894A (es) | Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. | |
| DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| ECSP19027780A (es) | Derivados de 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol 3-cinasa delta y gamma | |
| BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
| BR112015020787A2 (pt) | inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| BR112014007694A2 (pt) | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)óxi)naftaleno-1-il)ureias como inibidores de p38 map cinase | |
| GT201500218A (es) | Compuesto | |
| BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer | |
| ECSP14013275A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| DOP2014000271A (es) | Nueva forma de dosificacion y formulacion de abediterol | |
| UY33191A (es) | Derivados de pirazina | |
| UY33723A (es) | ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?. | |
| CO2018007610A2 (es) | Derivados de indano y su uso en terapias | |
| AR105921A1 (es) | Compuestos terapéuticos para el dolor y síntesis de estos |